TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12798518
Drug: Standard two-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard two-dose Yuzpe (levonorgestrel-ethinyl estradiol)
Study: 12798518
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Yuzpe (levonorgestrel-ethinyl estradiol)
Study: 12798518
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Yuzpe
Study: 12798518
Drug: Standard two-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard two-dose Yuzpe, Norethindrone-ethinyl estradiol, Single dose of Yuzpe
Study: 20883736
Drug: MnCC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MnCC vaccine
Study: 10973451
Drug: Quadrivalent polysaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent polysaccharide vaccine
Study: 1748257
Drug: Diet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet therapy
Study: 30906944
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein supplement
Study: 29031778
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg orally once a day for 6 years
Study: 29031778
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg orally once a day for 3 years
Study: 26156156
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm (colectomy and adjuvant chemotherapy)
Study: 19508679
Drug: 0.9 mg
Normalized name: estradiol 0.9 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mg rhTSH
Study: 16970138
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet every other day
Study: 16970138
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule on intervening days
Study: 15004251
Drug: Amlodipine (calcium-channel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (calcium-channel blocker)
Study: 15004251
Drug: Valsartan (AT1-receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (AT1-receptor blocker)
Study: 23283362
Drug: L-NMMA (NO
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (NO synthase inhibitor)
Study: 16393433
Drug: Oseltamivir 75
Normalized name: oseltamivir 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir 75 mg twice daily for 5 days
Study: 11075941
Drug: Oseltamivir 75
Normalized name: oseltamivir 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir 75 mg once or twice daily for 7 days
Study: 1555688
Drug: Standard hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard hormone replacement therapy (HRT) regimen
Study: 1555688
Drug: Reduced doses
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced doses of estradiol valerate (1/3 of standard)
Study: 1555688
Drug: Reduced doses
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced doses of progesterone (1/5 of standard)
Study: 3930255
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg dose of UDCA
Study: 3930255
Drug: 250, 500,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250, 500, or 750 mg doses of UDCA
Study: 3930255
Drug: UDCA (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA (various doses)
Study: 3930255
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of UDCA
Study: 3930255
Drug: Repeated daily
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated daily doses of UDCA
Study: 28682933
Drug: Capsaicin (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin (12 mg)
Study: 27039236
Drug: Budesonide/Formoterol (BUD/FM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/Formoterol (BUD/FM) 320/9 μg via pressurized metered-dose inhaler (pMDI)
Study: 20106824
Drug: Combined ramipril
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined ramipril at 10 mg/day and valsartan at 160 mg/day
Study: 20106824
Drug: Diuretic dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic dosage uptitration
Study: 17394248
Drug: Intracoronary administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary administration of selected CD133(+) and CD133(−) CD34(+) progenitor cells
Study: 21475009
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (Control)
Study: 17582923
Drug: Sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium oxybate (4.5 g to 9 g a day)
Study: 17582923
Drug: Sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium oxybate (at least 6 g a day)
Study: 17582923
Drug: Sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium oxybate (continuing treatment)
Study: 15693087
Drug: Vitamins C
Normalized name: MULTIVITAMINS CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamins C and E (500 mg vitamin C and 800 IU vitamin E daily)
Study: 2652569
Drug: MAG (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAG (20 mg/kg/day)
Study: 963865
Drug: Intranasal betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal betamethasone valerate aerosol for 28 days
Study: 963865
Drug: Oral antihistamine
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antihistamine compound
Study: 28778464
Drug: GET 73
Normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GET 73 (single and repeated doses)
Study: 24292304
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate infusion (3 doses of 250mg/kg per dose, 24 hours apart)
Study: 24292304
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusion (3 doses, 24 hours apart)
Study: 19624440
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate (IMN) self-administered vaginally at home
Study: 16711497
Drug: Oral analgesia
Normalized name: P-A-C Analgesic Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral analgesia (metamizole 575 mg/6 h p.o.)
Study: 15181066
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg TU i.m.
Study: 15181066
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 ml castor oil i.m.)
Study: 14630678
Drug: Oral capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral capecitabine 1250 mg/m² twice daily, days 1-14 every 21 days
Study: 14630678
Drug: i.v. bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. bolus 5-FU 425 mg/m² with i.v. leucovorin 20 mg/m² on days 1-5, repeated every 28 days
Study: 10468217
Drug: RRR-alpha-tocopherol 2
Normalized name: RRR-alpha-tocopheryl acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRR-alpha-tocopherol 2 g/d combined with L-ascorbic acid 3 g/d for 50 days
Study: 28860012
Drug: Continuous administration
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous administration of rocuronium (continuous-NMB-group)
Study: 9536541
Drug: Topical lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lithium succinate ointment (Efalith), applied twice daily.
Study: 8195977
Drug: Tc‐99m‐MDP (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tc‐99m‐MDP (20 mCi) injection and gamma-camera scanning
Study: 27464900
Drug: Daily Practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Practice Clothing
Study: 6397660
Drug: Semisynthetic human
Normalized name: INSULIN,NPH,HUMAN/SEMISYNTHETIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semisynthetic human insulin (Actrapid HM, Novo)
Study: 6397660
Drug: Purified pork
Normalized name: Insulin purified pork
DrugBank: Insulin pork (DB00071)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Purified pork insulin (Actrapid MC, Novo)
Study: 6397660
Drug: Both insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both insulin preparations (HM and MC)
Study: 19447770
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment alone (Control)
Study: 31479068
Drug: Open-label placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label placebo treatment for 3 weeks
Study: 31101782
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no medical treatment)
Study: 30246408
Drug: Reminiscence therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reminiscence therapy applied once a week for 8 weeks, 60 minutes per session
Study: 23331518
Drug: Quadrivalent HPV
Normalized name: HPV, quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent HPV vaccine (GARDASIL)
Study: 18839054
Drug: PF-PPS infusions
Normalized name: PF-06459988
DrugBank: PF-06459988 (DB14768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-PPS infusions (100-100 mg/day) for 5 days
Study: 10221723
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline infusions)
Study: 17719763
Drug: Tiotropium administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium administered via pMDI and spacer
Study: 17719763
Drug: Tiotropium administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium administered via DPI (Rotahaler)
Study: 15386563
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion mitoxantrone (CI-MTZ)
Study: 15191590
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of EMD and GTR
Study: 2700237
Drug: 50% solution
Normalized name: Osmoglyn 50% Solution
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50% solution of dimethylsulforoxide
Study: 911606
Drug: Enteric coated
Normalized name: Mesasal Enteric Coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric coated tablets (5 mg)
Study: 911606
Drug: Non-enteric coated
Normalized name: diclofenac sodium (enteric coated core) 50 MG / miSOPROStol (non-enteric coated mantle) 200 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-enteric coated tablets (5 mg)
Study: 22539587
Drug: Oral octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral octreotide 20 mg
Study: 22539587
Drug: Subcutaneous (sc)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (sc) octreotide 100 μg
Study: 17493510
Drug: Zinc +
Normalized name: GNP Cal Mag Zinc + D Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc + Oral Rehydration Solution (ORS)
Study: 2023770
Drug: Permanent programmable
Normalized name: penicillin G benzathine Prefilled Syringe [Permapen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permanent programmable infusion pumps
Study: 8553795
Drug: Intrathecal baclofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal baclofen infusion
Study: 6178497
Drug: Different dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different dose fractionation irradiation schedules
Study: 6178497
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of steroid or chemotherapy during the one‐month on‐study period
Study: 7607932
Drug: Nicotinamide 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide 80 mg/kg/day
Study: 7607932
Drug: Nicotinamide (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide (various doses)
Study: 7017496
Drug: Guacetisal (preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guacetisal (preparation B)
Study: 7017496
Drug: Bromexine, acetylsalicylic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromexine, acetylsalicylic acid, and codeine phosphate (preparation D)
Study: 30901487
Drug: Clonidine 75
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine 75 μg every third hour up to a maximum of four doses, then 75 μg twice daily until delirium free for 2 days, discharge, or a maximum of 7 days of treatment
Study: 25623393
Drug: Intravenous golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous golimumab plus methotrexate (MTX)
Study: 23322512
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (7,000 IU daily)
Study: 17724802
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg/d
Study: 16286164
Drug: Low-dose laser
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose laser
Study: 16286164
Drug: High-dose laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose laser
Study: 10214567
Drug: ADCON-L anti-adhesion
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADCON-L anti-adhesion barrier gel
Study: 7783536
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg prednisone added to the current daily dose, tapering off to baseline over 18 weeks
Study: 2215615
Drug: Lovastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (20 mg twice a day) and colestipol (10 g three times a day)
Study: 2215615
Drug: Niacin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin (1 g four times a day) and colestipol (10 g three times a day)
Study: 26695932
Drug: Twice per
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice per week (TPW) delivery of family-based childhood obesity programme
Study: 24429536
Drug: Zinc supplements
Normalized name: Zinc Supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplements twice daily
Study: 8657050
Drug: Low maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low maintenance doses of clozapine with concomitant neuroleptic therapy
Study: 17426908
Drug: Methylprednisolone (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (500 mg for 5 days)
Study: 8068956
Drug: Fractionated total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractionated total body irradiation (1,320 cGy) and high-dose etoposide (60 mg/kg) followed by allogeneic bone marrow transplantation (BMT)
Study: 3180635
Drug: Once-daily regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily regimen (2 mg phenobarbital tablet)
Study: 8172088
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 2.5 mg (100,000 IU) cholecalciferol (vitamin D3)
Study: 2963793
Drug: Nifedipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (5 mg three times a day rising to 20 mg three times a day)
Study: 30653372
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy activity pacing intervention
Study: 30653372
Drug: Typical occupational
Normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typical occupational therapy program (control)
Study: 26918853
Drug: Bilastine 10
Normalized name: Bilastine 10 mg orodispersible tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilastine 10 mg
Study: 25288512
Drug: Low-dose cannabis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose cannabis (5.5 mg THC)
Study: 20220045
Drug: Regimen A
Normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A (oral casopitant [150 mg day 1, 50 mg days 2 and 3] and warfarin [days 1-10])
Study: 20220045
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B (oral casopitant 60 mg and warfarin [days 1-14])
Study: 18069011
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (ESWT) at energy density of 0.55 mJ/mm(2) (1000 impulses)
Study: 18069011
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment with a dummy electrode
Study: 9539614
Drug: 6% hydroxyethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% hydroxyethyl starch (200/0.5) solution
Study: 7840167
Drug: DHEA (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (500 mg)
Study: 96459
Drug: Biperiden treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biperiden treatment
Study: 7065831
Drug: Standard three-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard three-week treatment
Study: 31433782
Drug: Myrtus communis
Normalized name: MYRTUS COMMUNIS TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myrtus communis herbal ointment
Study: 31433782
Drug: Anti-hemorrhoid ointment
Normalized name: benzocaine Topical Ointment [Americaine Hemorrhoidal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-hemorrhoid ointment
Study: 30237155
Drug: Immediate compression
Normalized name: oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate compression therapy (multilayer bandaging or compression hosiery, pressure 35 mm Hg)
Study: 27554689
Drug: No compression
Approvals — FDA: no, EMA: no, PMDA: no
Description: No compression therapy
Study: 19917869
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (anthracycline/taxane-based)
Study: 2198635
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg (single dose) + Hydrochlorothiazide 50 mg
Study: 2198635
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of Captopril 50 mg + Hydrochlorothiazide 50 mg
Study: 2198635
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of Captopril 50 mg + Hydrochlorothiazide 50 mg
Study: 31155415
Drug: delNS1‐H5N1 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: delNS1‐H5N1 vaccine at 6.8 log10 TCID50/subject
Study: 31155415
Drug: delNS1‐H5N1 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: delNS1‐H5N1 vaccine at 7.5 log10 TCID50/subject
Study: 31155415
Drug: delNS1‐H5N1 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: delNS1‐H5N1 vaccine after 2nd immunization
Study: 26646074
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (according to Touch Therapy) for four days from the first day postnatal
Study: 19228234
Drug: Gold standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold standard treatment (acetaminophen/paracetamol or non-steroidal anti-inflammatory drugs, and exercise and/or physical therapy)
Study: 19228234
Drug: Traditional and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional and non-traditional treatments
Study: 17708864
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (calcium supplement)
Study: 15371985
Drug: Trimethoprim 160
Normalized name: trimethoprim 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim 160 mg orally twice daily for 4 days
Study: 15371985
Drug: Rifampin 600
Normalized name: rifampin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 600 mg orally once daily for 5 days
Study: 9439556
Drug: Gliclazide (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide (80 to 320 mg/d) for 2 years
Study: 2846022
Drug: Prazosin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (0.5 mg orally)
Study: 31157575
Drug: Itraconazole pulse
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole pulse therapy (Group I)
Study: 31157575
Drug: Combined long-pulsed
Normalized name: Long-acting sulfonamide combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined long-pulsed Nd:Yag laser and itraconazole pulse therapy (Group II)
Study: 29701045
Drug: Subcutaneous embedding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous embedding of thumb-tack needle combined with mytear
Study: 21218643
Drug: Phloroglucinol 80
Normalized name: phloroglucinol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phloroglucinol 80 mg daily for 3 days
Study: 15390130
Drug: Dopamine agonists
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine agonists (either in monotherapy or in combination)
Study: 14617226
Drug: Pramlintide (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramlintide (120 μg bid) + insulin
Study: 3907825
Drug: Cyclophosphamide at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide at a dose of 1500 mg/m2 every 3 weeks for 1 year
Study: 27219721
Drug: 7-layer-coating implant
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7-layer-coating implant
Study: 30547305
Drug: Standard TKA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard TKA implant
Study: 22230474
Drug: 8 g
Normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g mushroom powder
Study: 22230474
Drug: 16 g
Normalized name: Maltsupex, 16 g/15 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 g mushroom powder